<DOC>
	<DOCNO>NCT00486889</DOCNO>
	<brief_summary>Pompe disease ( also know glycogen storage disease Type II ) cause deficiency critical enzyme body call acid alpha-glucosidase ( GAA ) . Normally , GAA use body 's cell break glycogen ( stored form sugar ) within specialized structure call lysosome . In patient Pompe disease , excessive amount glycogen accumulates store various tissue , especially heart skeletal muscle , prevents normal function . The overall objective study evaluate long-term growth development patient infantile-onset Pompe disease alglucosidase alfa 1 year age . Patients follow 10-year period .</brief_summary>
	<brief_title>Growth Development Study Alglucosidase Alfa .</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<mesh_term>Glycogen Storage Disease</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<criteria>The patient patient 's legal guardian must provide sign , inform consent prior perform studyrelated procedure ; The patient must confirm diagnosis Pompe disease determine deficient endogenous acid alphaglucosidase ( GAA ) activity GAA mutation analysis ; The patient must &lt; 1 year age time study enrollment ( receive alglucosidase alfa treatment 1 year age ) , patient must 1 year 24 month age must initiate alglucosidase alfa treatment prior turn 1 year age . The patient participate another clinical study use alglucosidase alfa investigational therapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Glycogenesis 2</keyword>
</DOC>